Drug Profile
Nesuparib - Jeil Pharmaceuticals
Alternative Names: JPI-547; NOV 1402; NOV140201Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Developer Jeil Pharmaceutical; Onconic Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors; Tankyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase I Pancreatic cancer
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in South Korea (PO)
- 21 Apr 2023 Phase-I clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) (PO) (NCT05257993) (Jeil Pharmaceutical pipeline, April 2023)
- 21 Apr 2023 Phase-II clinical trials in Ovarian cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) (PO) (NCT05475184) (Jeil Pharmaceutical pipeline, April 2023)